Rebecca Fannin of CNBC writes today, “From the start, SAIGroup’s strategy was differentiation.”
“SymphonyAI came together through a series of startups and acquisitions, positioned for retail, consumer packaged goods, financial services, manufacturing, media and the public sector. Building on the momentum, he [Romesh Wadhwani] expanded the business with two more health industry-specific AI companies. ConcertAI, launched in 2018, is pinpointing biotech. RhythmX AI, rolled out this October with a $50 million investment and run by CEO Deepthi Bathina, former chief clinical product officer at Humana, is a gen AI-based platform for physicians and healthcare systems to offer personalized patient care.”
Read the full piece here: